At ESMO, Amgen reported that an Imdelltra (tarlatamab) regimen combined with AstraZeneca’s Imfinzi reduced the risk of death by 58% versus Imfinzi alone in a first-line maintenance setting for certain small cell lung cancer patients. The result was presented for a Phase 3 study cohort in the report. The report frames the finding as a step beyond the benchmark historically achieved in the maintenance space, with investors and clinicians focusing on magnitude of survival benefit and the safety profile associated with the bispecific T-cell engager strategy. The data add to the growing competition among next-generation immunotherapy combinations in small cell lung cancer and set up follow-on attention to patient selection criteria and long-term outcomes.